|
WO1997026328A1
(en)
|
1996-01-17 |
1997-07-24 |
Imperial College Innovations Limited |
Immunotherapy using cytotoxic t lymphocytes (ctl)
|
|
US6872518B2
(en)
|
1997-09-22 |
2005-03-29 |
University Of Rochester |
Methods for selecting polynucleotides encoding T cell epitopes
|
|
CA2337743C
(en)
|
1998-07-31 |
2015-07-07 |
Yoshihiro Oka |
Tumor antigen based on products of the tumor suppressor gene wt1
|
|
US6710172B1
(en)
|
1998-10-02 |
2004-03-23 |
Ludwig Institute For Cancer Research |
Tumor antigens and CTL clones isolated by a novel procedure
|
|
US6407063B1
(en)
*
|
1998-10-02 |
2002-06-18 |
Ludwig Institute For Cancer Research |
Tumor antigens and CTL clones isolated by a novel procedure
|
|
GB9823897D0
(en)
|
1998-11-02 |
1998-12-30 |
Imp College Innovations Ltd |
Immunotherapeutic methods and molecules
|
|
ATE407206T1
(de)
*
|
1998-11-10 |
2008-09-15 |
Univ Rochester |
Methoden zu herstellung von genbanken
|
|
WO2000044774A2
(en)
|
1999-01-27 |
2000-08-03 |
The University Of South Florida |
Inhibition of stat3 signal transduction for human cancer therapy
|
|
EP1118661A1
(en)
*
|
2000-01-13 |
2001-07-25 |
Het Nederlands Kanker Instituut |
T cell receptor libraries
|
|
US7572631B2
(en)
*
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6797514B2
(en)
*
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US20030235908A1
(en)
*
|
2000-02-24 |
2003-12-25 |
Xcyte Therapies, Inc. |
Activation and expansion of cells
|
|
US20030119185A1
(en)
*
|
2000-02-24 |
2003-06-26 |
Xcyte Therapies, Inc. |
Activation and expansion of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
EP1268763A2
(en)
|
2000-03-28 |
2003-01-02 |
University Of Rochester |
Methods of producing a library and methods of selecting polynucleotides
|
|
EP1280889B1
(en)
*
|
2000-05-11 |
2007-08-29 |
Baylor Research Institute |
Compositions and methods for producing antigen-presenting cells
|
|
US20020019048A1
(en)
*
|
2000-05-25 |
2002-02-14 |
Ronald Berenson |
Methods for restoring or enhancing T-cell immune surveillance following naturally or artificially induced immunosuppression
|
|
DE10112851C1
(de)
*
|
2001-03-16 |
2002-10-10 |
Gsf Forschungszentrum Umwelt |
Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
|
|
WO2003033520A2
(en)
|
2001-09-24 |
2003-04-24 |
University Of Pittburgh Of The Commonwealth System Of Higher Education |
Anticancer vaccine and diganostic methods and reagents
|
|
US20040175373A1
(en)
*
|
2002-06-28 |
2004-09-09 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
US20050084967A1
(en)
*
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
US7638122B2
(en)
|
2003-03-07 |
2009-12-29 |
University Of South Florida |
Stat3 antagonists and their use as vaccines against cancer
|
|
US20040224402A1
(en)
*
|
2003-05-08 |
2004-11-11 |
Xcyte Therapies, Inc. |
Generation and isolation of antigen-specific T cells
|
|
EP1663308A1
(en)
*
|
2003-09-22 |
2006-06-07 |
Xcyte Therapies, Inc |
Compositions and methods to accelerate hematologic recovery
|
|
DE10344799A1
(de)
|
2003-09-26 |
2005-04-14 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
|
DE102004023187A1
(de)
|
2004-05-11 |
2005-12-01 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
|
WO2006031221A1
(en)
*
|
2004-09-13 |
2006-03-23 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Compositions comprising t cell receptors and methods of use thereof
|
|
ES2319286T3
(es)
|
2004-10-02 |
2009-05-06 |
Immatics Biotechnologies Gmbh |
Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
|
|
WO2007044033A2
(en)
*
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
|
DE102005013846A1
(de)
|
2005-03-24 |
2006-10-05 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
|
EP1717245B1
(en)
|
2005-04-26 |
2011-06-08 |
Immatics Biotechnologies GmbH |
T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
|
|
PT2327763T
(pt)
*
|
2005-08-05 |
2018-05-11 |
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh |
Geração de células t específicas de antigénios
|
|
PL1760089T3
(pl)
|
2005-09-05 |
2010-03-31 |
Immatics Biotechnologies Gmbh |
Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
|
|
ES2341802T3
(es)
|
2005-09-05 |
2010-06-28 |
Immatics Biotechnologies Gmbh |
Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
|
|
EP1951281B1
(en)
|
2005-10-17 |
2015-04-15 |
Sloan Kettering Institute For Cancer Research |
Wt1 hla class ii-binding peptides and compositions and methods comprising same
|
|
EP3117836A1
(en)
|
2006-04-10 |
2017-01-18 |
Sloan Kettering Institute For Cancer Research |
Immunogenic wt-1 peptides and uses thereof
|
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
EP1932537A1
(en)
*
|
2006-12-12 |
2008-06-18 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Expression of transgenic T cell receptors in LAK-T cells
|
|
PL2562184T3
(pl)
|
2007-07-27 |
2016-03-31 |
Immatics Biotechnologies Gmbh |
Nowe immunogenne epitopy do immunoterapii
|
|
SI2183361T1
(sl)
|
2007-07-27 |
2015-09-30 |
Immatics Biotechnologies Gmbh |
Nova imunoterapija proti nevronalnim in možganskim tumorjem
|
|
PL2105501T3
(pl)
|
2008-03-27 |
2016-03-31 |
Immatics Biotechnologies Gmbh |
Innowacyjna immunoterapia przeciwko nowotworom neuronów i mózgu
|
|
NO2119726T3
(OSRAM)
|
2008-05-14 |
2015-05-23 |
|
|
|
WO2010011994A2
(en)
|
2008-07-25 |
2010-01-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Polypeptides and uses thereof
|
|
DK2172211T3
(en)
|
2008-10-01 |
2015-02-16 |
Immatics Biotechnologies Gmbh |
Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
|
|
JP6069755B2
(ja)
|
2008-11-24 |
2017-02-01 |
ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー |
高親和性ｔ細胞受容体およびその用途
|
|
US8467973B2
(en)
*
|
2009-07-28 |
2013-06-18 |
Promising Future, Llc |
Pairing processes for preparing alloreactive cytotoxic T cells
|
|
GB0917094D0
(en)
|
2009-09-29 |
2009-11-11 |
Ucl Biomedica Plc |
T-cell receptor
|
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
|
GB201019331D0
(en)
|
2010-03-19 |
2010-12-29 |
Immatics Biotechnologies Gmbh |
Methods for the diagnosis and treatment of cancer based on AVL9
|
|
EP2802347B1
(en)
|
2012-01-13 |
2019-01-09 |
Memorial Sloan Kettering Cancer Center |
Immunogenic wt-1 peptides and methods of use thereof
|
|
SI2945647T1
(sl)
|
2013-01-15 |
2021-01-29 |
Memorial Sloan Kettering Cancer Center |
Imunogeni peptidi WT-1 in postopki za uporabo le-teh
|
|
US10815273B2
(en)
|
2013-01-15 |
2020-10-27 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 peptides and methods of use thereof
|
|
TWI775117B
(zh)
|
2013-08-05 |
2022-08-21 |
德商伊瑪提克斯生物科技有限公司 |
新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
|
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
|
GB201408255D0
(en)
|
2014-05-09 |
2014-06-25 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
|
|
GB201411037D0
(en)
|
2014-06-20 |
2014-08-06 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
|
|
CA2955984A1
(en)
|
2014-07-22 |
2016-01-28 |
The University Of Notre Dame Du Lac |
Molecular constructs and uses thereof
|
|
SG10202102698VA
(en)
|
2014-12-23 |
2021-04-29 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
|
|
GB201501017D0
(en)
|
2014-12-23 |
2015-03-04 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
|
|
ES2983924T3
(es)
|
2015-03-27 |
2024-10-28 |
Immatics Biotechnologies Gmbh |
Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
|
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
|
IL308735A
(en)
|
2015-07-01 |
2024-01-01 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
RS61203B1
(sr)
|
2015-07-06 |
2021-01-29 |
Immatics Biotechnologies Gmbh |
Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raka jednjaka i drugih malignih tumora
|
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
|
IL302705A
(en)
|
2016-03-01 |
2023-07-01 |
Immatics Biotechnologies Gmbh |
Peptides, combination of peptides, and cell-based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
|
|
GB201603987D0
(en)
|
2016-03-08 |
2016-04-20 |
Immatics Biotechnologies Gmbh |
Uterine cancer treatments
|
|
GB201604458D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against cancers
|
|
AU2017247607B2
(en)
|
2016-04-06 |
2021-08-19 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against AML and other cancers
|
|
TWI796299B
(zh)
|
2016-08-26 |
2023-03-21 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
|
TWI796314B
(zh)
|
2017-01-27 |
2023-03-21 |
德商英麥提克生物技術股份有限公司 |
用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
|
|
WO2018189152A2
(en)
|
2017-04-10 |
2018-10-18 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
|
|
EP3725327A3
(en)
|
2017-04-10 |
2021-01-20 |
Immatics Biotechnologies GmbH |
Peptides and combination thereof for use in the immunotherapy against cancers
|
|
TW201841934A
(zh)
|
2017-04-10 |
2018-12-01 |
德商英麥提克生物技術股份有限公司 |
用於治療癌症免疫治療的新穎肽及其肽組合物
|
|
CR20210169A
(es)
|
2017-07-07 |
2021-06-10 |
Immatics Biotechnologies Gmbh |
NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO DE LA INMUNOTERAPIA CONTRA EL CÁNCER DE PULMÓN, INCLUYENDO EL NSCLC, EL SCLC Y OTROS CÁNCERES (Divisional 2020-0059)
|
|
WO2019007974A1
(en)
|
2017-07-07 |
2019-01-10 |
Immatics Biotechnologies Gmbh |
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
|
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
TW202016131A
(zh)
|
2018-05-16 |
2020-05-01 |
德商英麥提克生物技術股份有限公司 |
用於抗癌免疫治療的肽
|
|
CN112512538A
(zh)
*
|
2018-05-18 |
2021-03-16 |
国家儿童医疗中心 |
改进的靶向t细胞疗法
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US10925947B2
(en)
|
2018-06-29 |
2021-02-23 |
Immatics Biotechnologies Gmbh |
A*03 restricted peptides for use in immunotherapy against cancers and related methods
|
|
TW202019955A
(zh)
|
2018-07-31 |
2020-06-01 |
德商英麥提克生物技術股份有限公司 |
B*07 限制肽和肽組合的抗癌免疫治療和相關方法
|
|
TW202028224A
(zh)
|
2018-09-17 |
2020-08-01 |
德商英麥提克生物技術股份有限公司 |
B*44限制肽在抗癌免疫治療的用途和相關方法
|
|
TW202024121A
(zh)
|
2018-09-18 |
2020-07-01 |
德商英麥提克生物技術股份有限公司 |
A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
|
|
CN109294995B
(zh)
*
|
2018-09-30 |
2020-08-04 |
北京鼎成肽源生物技术有限公司 |
一种rfft1细胞
|
|
CN110408657B
(zh)
*
|
2018-09-30 |
2021-03-16 |
北京鼎成肽源生物技术有限公司 |
一种afft1细胞的构建方法
|
|
WO2020123716A1
(en)
|
2018-12-11 |
2020-06-18 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
|
TW202039535A
(zh)
|
2018-12-18 |
2020-11-01 |
德商英麥提克生物技術股份有限公司 |
B*08限制肽和肽組合物抗癌免疫治療和相關方法
|
|
SG11202109225WA
(en)
|
2019-03-08 |
2021-09-29 |
Obsidian Therapeutics Inc |
Cd40l compositions and methods for tunable regulation
|
|
CN113966397A
(zh)
|
2019-03-08 |
2022-01-21 |
黑曜石疗法公司 |
人碳酸酐酶2组合物和用于可调调节的方法
|
|
EP3983537A1
(en)
|
2019-06-12 |
2022-04-20 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
CA3140668A1
(en)
|
2019-06-12 |
2020-12-17 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
JP7692897B2
(ja)
|
2019-09-10 |
2025-06-16 |
オブシディアン セラピューティクス， インコーポレイテッド |
調節可能な制御のためのｃａ２－ｉｌ１５融合タンパク質
|
|
CA3163838A1
(en)
|
2020-01-08 |
2021-07-15 |
Vipin Suri |
Compositions and methods for tunable regulation of transcription
|
|
WO2021144020A1
(en)
|
2020-01-15 |
2021-07-22 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding prame
|
|
WO2021262773A1
(en)
|
2020-06-22 |
2021-12-30 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of cas nucleases
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的ｈｌａ展示肽
|
|
WO2022184805A1
(en)
|
2021-03-03 |
2022-09-09 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
|
|
WO2022233956A1
(en)
|
2021-05-05 |
2022-11-10 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding prame
|
|
PE20240779A1
(es)
|
2021-07-27 |
2024-04-17 |
Immatics Biotechnologies Gmbh |
Proteinas de union a antigenos que se unen especificamente a ct45
|
|
WO2025021979A1
(en)
|
2023-07-27 |
2025-01-30 |
Immatics Biotechnologies Gmbh |
Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
|
|
WO2025040598A2
(en)
|
2023-08-18 |
2025-02-27 |
Immatics Biotechnologies Gmbh |
Peptides displayed by mhc for use in immunotherapy against different types of cancer
|